CALCITRIOL INJECTION SOLUTION

Država: Kanada

Jezik: angleščina

Source: Health Canada

Kupite ga zdaj

Prenos Lastnosti izdelka (SPC)
16-11-2017

Aktivna sestavina:

CALCITRIOL

Dostopno od:

FRESENIUS KABI CANADA LTD

Koda artikla:

A11CC04

INN (mednarodno ime):

CALCITRIOL

Odmerek:

1MCG

Farmacevtska oblika:

SOLUTION

Sestava:

CALCITRIOL 1MCG

Pot uporabe:

INTRAVENOUS

Enote v paketu:

1ML

Tip zastaranja:

Prescription

Terapevtsko območje:

VITAMIN D

Povzetek izdelek:

Active ingredient group (AIG) number: 0113628002; AHFS:

Status dovoljenje:

CANCELLED POST MARKET

Datum dovoljenje:

2023-03-10

Lastnosti izdelka

                                PRODUCT MONOGRAPH
PR
CALCITRIOL INJECTION
1 MCG/ML AND 2 MCG/ML
Vitamin D
3
metabolite
FRESENIUS KABI CANADA LTD.
165 Galaxy Blvd, Suite 100
Date of Revision:
Toronto, ON, M9W 0C8
November 16, 2017
Submission Control No.: 199558
Calcitriol Injection – Product Monograph
_ _
Page 2 of 23
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
3
WARNINGS AND PRECAUTIONS
...............................................................................................
4
ADVERSE REACTIONS
.................................................................................................................
6
DRUG INTERACTIONS
.................................................................................................................
8
DOSAGE AND ADMINISTRATION
.............................................................................................
9
OVERDOSAGE
.............................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
10
STORAGE AND STABILITY
.......................................................................................................
12
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
12
DOSAGE FORMS, COMPOSITION AND
PACKAGING...........................................................
12
PART II: SCIENTIFIC INFORMATION
...................................................................................
13
PHARMACEUTICAL INFORMATION
......
                                
                                Preberite celoten dokument
                                
                            

Dokumenti v drugih jezikih

Lastnosti izdelka Lastnosti izdelka francoščina 16-11-2017

Opozorila o iskanju, povezana s tem izdelkom